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Abstract
Helicobacter pylori is the leading cause of gastritis, peptic ulcer disease and gastric
adenocarcinoma and lymphoma in humans. Due to the decreasing efficacy of anti-H. pylori
antibiotic therapy in clinical practice, there is renewed interest in the development of anti-H. pylori
vaccines. In this study an in silico-based approach was utilized to develop a multi-epitope DNA-
prime/peptide-boost immunization strategy using informatics tools. The efficacy of this construct
was then assessed as a therapeutic vaccine in a mouse model of gastric cancer induced by chronic
H. pylori infection. The multi-epitope vaccine administered intranasally induced a broad immune
response as determined by interferon-gamma production in ELISpot assays. This was associated
with a significant reduction in H. pylori colonization compared with mice immunized with the
same vaccine intramuscularly, given an empty plasmid, or given a whole H. pylori lysate
intranasally as the immunogen. Total scores of gastric histological changes were not significantly
different among the 4 experimental groups. These results suggest that further development of an
epitope-based mucosal vaccine may be beneficial in eradicating H. pylori and reducing the burden
of the associated gastric diseases in humans.
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Helicobacter pylori represents a significant public health challenge since it causes chronic
gastritis and significantly increases the risk of developing peptic ulcer disease and gastric
cancer [1]. H. pylori infection is highly prevalent, particularly in developing countries. The
strong epidemiological linkage between H. pylori and distal (non-cardia) cancer led the
World Health Organization's International Agency for Cancer Research branch to classify H.
pylori as a definite (type I) carcinogen in 1994 [2], a conclusion confirmed by the same
agency last year [3].
The co-evolution of H. pylori with human beings over tens of thousands of years and the
inverse relationship between H. pylori and certain conditions, such as gastroesophageal
reflux disease, has led to the suggestion that persistent H. pylori infection may provide some
benefit to humanity, especially in the developed world [4]. Nevertheless, for most infected
individuals the balance of evidence supports eradicating H. pylori to prevent gastritis, ulcer
disease and gastric cancer, especially where H. pylori and gastric cancer are very common,
such as in the Asian-Pacific region [5].
Current treatments to eradicate H. pylori involve the use of multiple antibiotics in
combination with acid suppression medication over 1-2 weeks, an approach that has
changed little over the last 3 decades since H. pylori was first identified [1]. Because of
antibiotic resistance (especially to metronidazole and clarithromycin), H. pylori is more
difficult to eradicate now than it had been formerly [6] leading to renewed interest in
developing alternative therapeutic strategies such as vaccines [7]. Vaccination against H.
pylori may be a particularly attractive choice as the most practical way to avoid H. pylori-
associated gastric cancer in the developing world [8].
In humans, H. pylori stimulates an intense gastric inflammatory response that persists over
the course of infection that typically lasts many decades. Animal models have established
that the pathogenesis of gastric diseases induced by H. pylori is related to the Th1-skewed
T-cell response and that humoral immunity does not provide protection against infection.
Despite the generation of robust cellular and humoral immune responses, spontaneous
eradication of the organism is extremely rare in humans [1], likely related to several
properties of the bacterium that help it evade natural immune responses and allow
persistence [4]. While normal immune mechanisms fail to eradicate H. pylori, some
prophylactic and therapeutic vaccines strategies using a wide variety of H. pylori antigens
have been reported to successfully eradicate H. pylori from mice and in a few studies in
human volunteers [7]. Nevertheless the correlates of gastric immunity to H. pylori are not
well defined and the optimal choice of antigen and best delivery method for further clinical
development remain to be determined.
In order to advance our H. pylori vaccine strategy we used a gene-to-vaccine approach,
incorporating multiple epitopes in a DNA-prime/peptide boost approach as previously
described [9], using informatics tools that have been successfully applied to AIDS, TB,
smallpox and tularemia vaccine development [9-13]. We present our initial findings on the
efficacy of this construct as a therapeutic vaccine in a mouse model of gastric cancer
induced by chronic H. pylori infection. Our results suggest that a broad-spectrum epitope-
driven immune response against H. pylori antigens can lead to successful eradication of the
organism.
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Mice, H. pylori infection and overall experimental plan
A total of 80 male and female C57BL/6 mice deficient in the CDKN1B gene encoding p27
were used in this study. Because female heterozygous CDKN1B-deficient mice are sterile,
the mice for this study were derived from breeding male homozygous deficient to female
heterozygotes and then identifying homozygous deficient pups by genotyping. Heterozygote
founders of this colony had been originally purchased from Jackson laboratories (Jackson
Labs, Bar Harbor, ME). All studies were performed in full compliance with the standards of
the Rhode Island Hospital Institutional Animal Care and Use Committee and in accordance
with NIH publications entitled “Principles for Use of Animals” and “Guide for the Care and
Use of Laboratory Animals.”
At 6 weeks of age mice were infected with 109 H. pylori strain SS1 in 0.1 mL PBS by
gavage on 3 occasions over 1 week using a balled animal feeding needle as previously
described [14].
There were 4 experimental groups (20 mice per group); the experimental design is shown in
Figure 1. At weeks 11-15 of age, mice were given doses of a H. pylori SS1 lysate, an empty
plasmid (“pVAX control”) or a DNA based vaccine intramuscularly or intranasally. At ages
17 and 18 weeks mice were given a boost of intranasal peptides formulated in liposomes (or
empty liposome as a control).
All mice were maintained in micro-isolator cages to reduce inter-cage Helicobacter
infection and allowed access to Harlan Teklad Global Diet 2018 (Harlan, Indianapolis, IN)
and water ad libitum, in accordance with the guidelines set forth by the Institutional Animal
Care and Use Committee of Rhode Island Hospital. At 51 weeks of age (45 weeks after H.
pylori infection) mice were euthanized by cervical dislocation under isoflurane anesthesia
for bacteriological, immunological and histological analyses.
Immunizations
A lysate of H. pylori strain SS1 was prepared by French press and clarified by centrifugation
as described previously [15]. 200 microgram of H. pylori lysate with 10 microgram E. coli
heat-labile LT (R192G) adjuvant in 20 microliters PBS was administered intranasally once
weekly for 5 weeks. [16].
In the group receiving pVAX control intranasally, 100 micrograms of an empty plasmid was
given with 10 microgram LT (R192G) adjuvant in 20 microliters PBS on 3 occasions over 5
weeks (weeks 11,13 and15), and 20 microliters PBS only was given intranasally on two
occasions (weeks 12 and 14).
In the group receiving DNA vaccine intramuscularly, 100 micrograms of DNA in 0.1
milliliter PBS was given into the flank on 3 occasions over 5 weeks (weeks 11,13 and 15)
and 20 microliters PBS only was given intranasally on two occasions (weeks 12 and 14).
In the group receiving DNA vaccine intranasally, 100 micrograms of DNA was given with
10 microgram LT (R192G) adjuvant in 20 microliters PBS on 3 occasions over 5 weeks
(weeks 11,13 and 15) and 20 microliters PBS only was given intranasally on two occasions
(weeks 12 and 14).
To boost responses in the two DNA-based vaccine arms, a 10 microliter volume of
liposomal peptide vaccines (50 microgram) with 20 microgram immunostimulatory CpG
oligonucleotides and 10 microgram LT (R192G) were given intranasally at week 17 and at
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week 19. All peptides were formulated together in a single preparation so that all the mice
treated with peptides receive the identical peptide combination. The other two groups of
mice (H. pylori lysate, pVax control) were given empty liposomes instead, at the same
timepoints.
Multi-epitope DNA vaccine engineering
Epitope sequences were concatenated to form two multi-epitope genes (termed HelicoVax A
and HelicoVax B), each containing 25 HLA Class II epitopes that were identified by
immunoinformatics methods, as described previously [17]. The detailed final composition
and epitope order are listed in Supplemental Table 1 and Supplemental Table 2. All mice in
the DNA vaccine groups received both HelicoVax A and HelicoVax B. Initially, epitopes
were assembled in a random sequence. To avoid creation of novel epitopes at epitope
junctions, an algorithm which iteratively re-orders epitopes to reduce junctional
immunogenicity (VaccineCAD) was used to optimize epitope order [10]. In addition, Gly-
Pro-Gly-Pro-Gly spacer sequences were engineered between some epitopes to optimize
epitope processing, where re-ordering by VaccineCAD did not sufficiently reduce potential
junctional immunogenicity [18].
A Kozak sequence was engineered upstream of the coding sequence for efficient translation
initiation. To target the immunogens to the Class II processing pathway, the tissue
plasminogen activator (tPA) leader sequence (MQMSPALTCLVLGLALVFGEGSA) was
placed upstream of epitope sequences to direct translation products to the secretory pathway.
A histidine tag was incorporated downstream of the epitope sequences followed by two stop
codons. Genes were synthesized by GeneArt (Burlingame, CA) and subcloned at pre-
determined flanking restriction sites into pVAX1 (Invitrogen, Carlsbad, CA), a DNA
vaccine vector that accommodates FDA recommendations for construction of plasmid DNA
vaccines [19]. High purity plasmids for immunizations were prepared by PureSyn, Inc.
(Malvern, PA) at pre-clinical grade.
Peptide vaccine preparation
Peptides were manufactured using 9-fluoronylmethoxycarbonyl (Fmoc) chemistry by New
England Peptide (Gardner, MA). Master batch records indicate that peptides were purified to
>80% as ascertained by analytical reversed phase HPLC and peptide mass was confirmed by
MALDI-TOF mass spectrometry.
The constituent peptides of the DNA vaccine were formulated in liposomes with
immunostimulatory CpG oligodeoxynucleotide (ODN) 1555 (5′-
GCTAGACGTTAGCGT-3′; Integrated DNA Technologies, Coralville, IA) [20] and heat-
labile enterotoxin, LT (R192G), kindly provided by Dr. John Clements (Tulane University).
Sterically stable cationic liposomes were prepared from three lipid components: 11.9 μmol
dioleylphosphatidylethanolamine, 7.9 μmol dimethylaminoethanecarbamol-cholesterol, and
1.1 μmol polyethylene glycol 2000-phosphatidyl-ethanolamine (Avanti Polar Lipids,
Alabaster, AL). The lipids were mixed, dried in a rotary evaporator and re-suspended in PBS
to make empty multi-lamellar vesicles. These vesicles were then sonicated for 2 min to
convert them into unilamellar liposomes. Unilamellar liposomes (10 μmol) were mixed with
CpG ODN (400 μg) and peptides (1 mg), flash frozen and freeze-dried overnight. To
encapsulate CpG ODN and peptides in liposomes, the resulting powder was re-suspended
with sterile distilled water and vortexed for 15 seconds every five minutes for 30 minutes at
room temperature. PBS and LT (R192G) were added to yield the final required vaccine
volume and LT dose, as described above. Liposome formulations were stored at 4°C until
use.
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H. pylori infection was quantified by real-time PCR of the SSA gene of H. pylori,
normalized for mouse stomach GAPDH expression, as previously described [14].
Gastric histology
Gastric histology was evaluated without knowledge of experimental group in H&E-stained
sections and scored for epithelial and inflammatory cell parameters using the criteria and
grading system of Rogers et al [21].
ELISpot assay
The frequency of epitope-specific splenocytes was determined by IFN-gamma ELISpot
assay using the Mabtech IFN-gamma ELISpot Kit according to the manufacturer's protocol
(Mariemont, OH). Briefly, spleens were harvested from groups of control and vaccinated
mice and mascerated to produce single cell splenocyte suspensions in RPMI-10% fetal
bovine serum-1% penicillin/streptomycin-1% L-glutamine-0.1% BME at a concentration of
3 × 106 cells/ml. Cells were transferred at 3×105/well to ELISpot plates pre-coated with
anti-murine IFN-gamma by the manufacturer and stimulated with 50 individual and 6 pools
of 5-10 peptides at 10 μg/ml in triplicate wells. Pools 1 to 3 correspond to the epitopes
contained in DNA vaccine construct A (HelicoVaxA) and pools 4 to 6 correspond to
epitopes present in DNA vaccine construct B (HelicoVaxB). Positive controls included cells
stimulated with Con A (2 μg/ml) or SS1 lysate (10 μg/ml); no-peptide stimulation served as
a negative control. ELISpot plates were incubated at 37°C, 5% CO2 for 2 days, washed,
incubated with a secondary HRP labeled anti-IFN-gamma antibody and developed by
addition of TMB substrate. Spot counts were determined by Zellnet, Inc. using a Zeiss
ELISpot plate reader. Results were recorded as the average number of spots over
background and adjusted to spots per one million cells seeded. Responses are considered
positive if the number of spots is: 1) at least twice greater than background, 2) greater than
50 spots forming cells per one million splenocytes over background (i.e. one response over
background per 20,000 splenocytes), and 3) statistically significant by Student's t-test in
comparison with the corresponding spot forming cell data set for other groups (p<0.05).
Statistics
Differences between experimental groups were compared by one-way analysis of variance
with Dunnett's multiple comparison test, or the non-parametric equivalent, Kruskal-Wallis
with Dunn's multiple comparison test, as appropriate (GraphPad Prism version 5.01,
GraphPad, La Jolla, CA).
Results
Multi-epitope DNA vaccine construction
We designed two DNA vaccines, HelicoVax A and HelicoVax B, each of which contains a
distinct set of 25 HLA class II epitopes (Figure 2 and Table 1). The epitopes were previously
identified using immunoinformatics methods that selected immunogenic and conserved
sequences from the H. pylori 26695 and J99 genomes [17]. Epitope sequences were
randomly concatemerized, at first. To avoid production of neo-epitopes at epitope junctions,
the VaccineCAD algorithm was used to re-arrange epitopes in an order that diminishes
potential junctional immunogenicity. The default order for each construct contained
significant predicted immunogenicity at two junctions in HelicoVax A and none in
HelicoVax B (EpiMatrix scores >10). Re-ordering of epitopes by VaccineCAD and insertion
of GPGPG spacers (24) produced sequences with minimized junctional immunogenicity
(EpiMatrix scores < 4.5) (Supplemental Data Tables 1 and 2).
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A small number of mice died due to peri-procedural complications, so that the final numbers
of mice available at study end were 18 in the lysate and DNA IM groups, 17 in the empty
plasmid control group and 19 in the DNA IN group.
The results of H pylori infection density evaluated by real-time PCR are shown in Figure 3.
Mice in the DNA IN group had the lowest numbers of bacteria, with 5 of the 19 mice having
no detectable H. pylori DNA (compared with 2 of 17 in the pVAX group, none of 18 in the
lysate group and 3 of 18 in the DNA IM group). Considerable variation in infection density
within each group was evident, but the median value for the DNA IN group (1.05) was
significantly lower than the median for each of the other 3 groups, lysate median 47.4,
pVAX median 25, DNA IM median 53.4 (P<0.001 versus lysate, P<0.01 versus pVAX, and
P<0.001 versus DNA IM).
Histology
Histological abnormalities in these mice are shown in Table 2, including the median (range)
scores for inflammation, epithelial defects, oxyntic atrophy, hyperplasia, metaplasia and
dysplasia, as well as total score. Overall, the histological changes were quite mild and
differences were only statistically significant for inflammation and dysplasia, when
comparing mice treated with pVAX versus lysate (less advanced histological changes in the
pVAX group, P<0.05 for inflammation, P<0.01 for dysplasia).
Immune responses
ELISpot assays of epitope-stimulated splenocytes in the DNA IN and DNA IM groups
demonstrated that 33/50 epitopes (66%) stimulated >50 interferon-gamma spot forming cells
per million splenocytes (Figure 4, gray bars), compared to only 2/50 epitopes (4%) which
were recognized in SS1 lysate-immunized animals (Figure 4, open bars). Additionally, all
peptide pools stimulated robust interferon-gamma production. There was no consistent
difference between intranasal (filled circles) and intramuscular (open circles) DNA
immunization on the single-epitope level, but intranasal vaccination generally was
associated with stronger responses, particularly among the most immunogenic epitopes.
Consistent with the colonization data, SS1 lysate and DNA IM groups, respectively,
stimulated 2 and 6 statistically significant responses when compared to the pVAX group,
while 23 significant responses were observed in the DNA IN group (P<0.05). pVAX alone
did not stimulate any statistically significant ELISpot responses
Discussion
The results of this study suggest that a DNA-prime/peptide-boost vaccine designed to
present multiple H. pylori epitopes has therapeutic efficacy when delivered intranasally to
mice previously infected by H. pylori. The multi-epitope vaccine induced a broad immune
response that led to a significant reduction in H. pylori colonization. In contrast, mice given
a whole H. pylori lysate or an empty plasmid intranasally as the immunogen, or immunized
with the same vaccine intramuscularly failed to eradicate the organism. These encouraging,
though preliminary, results suggest that further development of an epitope-based mucosal
vaccine against H. pylori can potentially lead to a novel approach to prevent H. pylori-
associated diseases such as peptic ulcer disease and gastric cancer in humans.
Importantly, the vaccine-induced immune response parallels what is observed in natural
infection. H. pylori infection dramatically influences the gastric leukocyte environment with
recruitment of T cell populations, primarily the CD4+ phenotype [22], that constitute an
enriched source (~1-10%) of H. pylori-specific T cells compared with peripheral T
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lymphocytes [23,24]. Gastric T cells isolated from biopsies of H. pylori-infected subjects
exhibit a predominantly proinflammatory Th1 phenotype characterized by a high frequency
of IFN-γ-secreting cells [22,25]. The finding that live H. pylori preferentially stimulates
production of IL-12 [26], which selects for Th1 cell development, may explain the finding
that the majority of Th cell clones derived from H. pylori-infected patients are comprised of
Th1 effector cells [23,27]. H. pylori pathogenesis also involves regulatory T cells (Tregs).
Depletion of CD4+/CD25hi Tregs from infected human donors leads to increased H. pylori-
specific memory T cell proliferation and IFN-gamma production in response to H. pylori
pulsed dendritic cells. Additionally, increased levels of CD4+/CD25hi/FoxP3+ regulatory T
cells have been observed in gastric and duodenal mucosa of H. pylori-infected humans [28].
Moreover, similar results have been described in mouse models of H. pylori infection
[29,30]. These findings underscore the importance of a Treg response in H. pylori
immunopathogenesis and suggest that persistence of H. pylori infection may be explained by
Treg-mediated suppression of pathogen-specific memory T-cells [31]. As Tregs contribute
to equilibrium between host and pathogen, inflammation is maintained at low levels,
allowing H. pylori to survive. Taken together, immunopathogenesis studies suggest that a
vaccine that elicits a strong Th1 response, like the CD4+ T-cell epitope-based vaccine
described here, should support the immune system's fight against H. pylori infection.
However, we appreciate that identifying correlates of vaccine efficacy against H. pylori
remains a major challenge [7].
The CDKN1B deficient mouse model was chosen for this study because it had been shown
to develop gastric cancer about 1 year after H. pylori infection, following a sequence of
progressive histological changes (gastritis, glandular atrophy, metaplasia and dysplasia)
similar to the events that appear during gastric carcinogenesis in humans infected by H.
pylori [14]. One of the aims of this study was to determine whether the therapeutic vaccine
could inhibit these progressive histological changes and thus prevent cancer in this model.
However histological changes in all four arms of this study were relatively mild, even in the
group that received no immunogen (the pVAX group). Indeed, histological abnormalities
evaluated at 45 week post-infection were, if anything, less severe in those mice that received
the pVAX construct than in mice that had been exposed to H. pylori lysate or the epitope
based H. pylori DNA vaccines. Although it might be assumed that reduction in H. pylori
colonization will lead to less inflammation and other features of gastric damage included in
the histological score, it is important to note that within groups of C57BL/6 mice
successfully infected by the SS1 H. pylori strain, there is an inverse relationship between the
bacterial load and the total gastritis score [32]. Another important consideration when
interpreting histological changes is the phenomenon of “post immunization gastritis” in
which successful elimination of H. pylori following vaccination is accompanied by a
transient increase of gastritis over a few weeks, though this ultimately abates with time [33].
The current study evaluated inflammation only at the end of the experiment and therefore
the kinetic changes in gastritis over the course of the 45 week infection period remains
unknown; it is conceivable that post-immunization gastritis (presumably absent in the pVAX
group) might account for some of the discrepancy between the histological scores and the H.
pylori colonization at 45 weeks post infection.
A limitation of the current study is that we did not include a group of mice that were
infected with H.pylori but were not subsequently subject to any subsequent experimental
manipulations at all (a true “negative control” group). Thus, we cannot state with certainty
that the DNA IM strategy or the HP lysate strategy (or indeed the pVAX control) did not
reduce H.pylori colonization. We can only state with certainty that the DNA IN strategy was
superior to the other 3 strategies. Indeed, because all mice in the study received LT as
adjuvant, a non-specific effect of adjuvant also cannot be entirely ruled out. We suspect that
the intranasal route to deliver the epitope-based DNA vaccine was more efficacious than the
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identical vaccine delivered intramuscularly because mucosal immunization likely produced
a more robust gastric mucosal cell-mediated immune response against H.pylori. However,
further studies will be necessary to directly test this hypothesis.
Despite decades of research, the immune response to H. pylori and, in particular, the
correlates of successful immunity necessary for H. pylori vaccination remain poorly
understood. Based upon many previous studies in animal models of infection it is known
that the production of antibody in the stomach (IgA) provides little or no protection against
H. pylori infection [34]. In contrast MHC Class II restricted T-cells including Th1, Th2 and
Th17 cells are important in mediating immunity in murine models [7]. In humans, chronic
infection by H. pylori is associated with robust immune and inflammatory responses that
nevertheless rarely succeed in eradicating the organism and decades long persistence is
typical, related in part to the strategy of H. pylori to survive and evade immune defenses [4].
The choice of the CDKN1B mouse as a model for testing the potential therapeutic efficacy
of an epitope based vaccine against H. pylori was predicated upon increased susceptibility of
these mice to gastric cancer and the opportunity to determine whether therapeutic
immunization against H. pylori could reduce recurrence of this highly clinically significant
endpoint. However, the deficiency of p27 in all lineages, including of the lymphoid lineages,
may have limited extrapolation from this model to other murine models for H. pylori
infection. For example, in contrast to wild-type mice the T cells of p27-deficient mice are
more susceptible to apoptosis following interleukin-2 withdrawal demonstrating the
importance of p27 in the survival of activated T-cells [35]. These mice also have reduced
proliferative capacity of their T-cells, especially the CD8+ subset [36]. While p27 deficiency
does not apparently affect the differentiation of T cells into Th1 versus Th2 subsets, [37]
exaggerated inflammatory responses have been noted in mice populated with p27 deficient
bone marrow [38] suggesting that deficiency of p27 in bone marrow-derived progenitor cells
can promote inflammatory responses. Furthermore, two groups have demonstrated failure of
T-cell tolerance in p27-deficient mice [39,40].
Taken together, these results demonstrate subtle but potentially important abnormalities in
the immune system of p27-deficient mice that should be borne in mind when extrapolating
from the current results to those that might be expected in wild type mice. Future studies are
planned using “humanized” HLA transgenic mice as a bridge to clinical vaccine
development.
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Outline of study design.
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Outline map of H. pylori DNA vaccine construct
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H. pylori colonization. Quantification of gastric H. pylori colonization was performed by
real-time PCR and expressed as the ratio of H. pylori's SSA gene to mouse GAPDH. Black
bars represent median value of each group. Data analysis by Kruskal-Wallis oneway
analysis of variance followed by Dunn's test demonstrate that the values for mice receiving
DNA IN group were significantly lower than each of the other groups.
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Cell-mediated response to immunization of p27-deficient mice with HelicoVax A and
HelicoVax B epitopes. Mice were primed with plasmid DNA vaccine and boosted with
peptide pools comprising the HelicoVax A and HelicoVax B epitope sets or vaccine vehicle
containing no epitopes. Splenocyte responses to individual and pooled epitopes were
measured by IFN–γ ELISpot. Data are the mean spot forming cells (SFC) per million
splenocytes for HelicoVax-vaccinated mice (filled bars), SS1 lysate-vaccinated mice (open
bars) and HelicoVax DNA IN (filled circles) and DNA IM (open circles) groups of mice.
Peptide pools 1 to 3 correspond to the epitopes contained in DNA vaccine construct A
(HelicoVaxA), pools 4 to 6 to DNA vaccine construct B (HelicoVaxB).
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Table 1
HelicoVax T-cell Epitopes. Column 1: peptide ID. Column 2: amino acid sequence. Column 3: GenBank




Number Location in Protein
HP 4001 NDNVRAYGGNIYEGVLINYYKAIDYMLLNDS GI-15611087 139-173
HP 4007 RSKSKAKVRINDLRWVFSQRLSALVG GI-15611162 73-99
HP 4009 MLLERSLIRVNKERLQTYLSLYANETSTRLSEV GI-15611210 141-171
HP 4018 GLHFLGVFRFAFLYKTQSVGLASKS GI-15611320 571-595
HP 4026 MHQYKRMQTYPVLFAIQKLALENN GI-15611443 152-176
HP 4029 PAIYFANSSISGYVFLGLKTKRVRLDA GI-15611469 42-69
HP 4032 AMGFNNYGAILGVRAFNRFAPYKTPIGINLGKN GI-15611480 9-38
HP 4034 DSMIEIVNANFSLVHRYYHQKAQILGHK GI-15611489 503-529
HP 4040 YDRWHGAFRLGYTYRINPFVGIYAQ GI-15611518 165-192
HP 4042 LYFLGGVLRHARGLAAFTNASTNSYKRL GI-15611528 22-49
HP4054 SDVVRTIEAYRMLRPLVIYPF GI-15611636 340-371
HP 4055 TINVYYFNHGNLSFTYRRQYSLYVGYR GI-15611681 67-101
HP 4060 LNTWLNMNALAPKILKALYAYGAQGINLGLNL GI-15611745 177-208
HP 4061 FALVVFVLSVLLMFKQVRIWIYQYH GI-15611753 174-201
HP 4064 HFSYKRYLINTLRKEFNFLGTPLILNA GI-15611840 245-272
HP 4065 MKNFSPLYCLKKLKKRHLIALSLPLLSY GI-15611844 14-42
HP 4067 CHALYNVGRISTYMLLGAITAGLGNS GI-15611862 53-84
HP 4068 KIMYYILPQVWAWKKWRAKSLEKYCDF GI-15611868 408-438
HP 4070 QESVKDAYSEFVFALKRLKILKAQMLELQKIN GI-15611883 112-140
HP 4071 YNTYYKAGGAEVKYFRPYSVYWVYGY GI-15611916 59-85
HP 4077 REEIEFMKRKYRLMWGKVADMSSVNK GI-15612040 126-153
HP 4087 MPPIYRAENGLLVIRPLIKVREASS GI-15612173 29-58
HP 4100 CKTMALALKALGVKRAMVVNGGGTD GI-15612266 95-125
HP 4111 QKYFNDYLGLSSYGIIKYNYAQANNEKIQQL GI-15612411 31-61
HP 4117 VWPFESLPSYLQVFVQIVPAYHGISLLG GI-15612444 59-86
HP 4119 EIKVSSRQKNVALARKLVVYFARLYTPNPTLSLAQF GI-15612482 49-78
HP 4120 GSSYHASLASVYLFERLAKIRARAILASEYR GI-15612485 318-345
HP 4126 GEWYLVAMAYNYGLRKVQNAIKAAGTSD GI-15612545 82-113
HP 4127 WKKLVKRFDVNYQFIPIIKNMLIGASVPQEFL GI-15612545 47-77
HP 4152 DTAYKMLKANPTLALSAE GI-15611119 723-740
HP 4153 DMLYKLNESLRIYQNVLSNNQDQL GI-15612318 39-62
HP 4154 SNRFMLLWKNRYTLAKVQSFKLEPG GI-15612384 78-102
HP 4156 FEKKLFVMNYPLTLYTTSPYGISEE GI-15611791 56-80
HP 4157 MEQVIQNYRMIVALIQNKLSDA GI-15611555 285-306
HP 4160 PFDLKLLEKEFYQNNATSLLVTS GI-15611379 245-267
HP 4164 NMELKKALRHYLYAQTSNMVINCV GI-15611135 173-196
HP 4165 GAFYKVWKNANAYIGTTGNPLGID GI-15611410 344-367

















Number Location in Protein
HP 4168 INSIPGYVKLFRKAYGSKVKID GI-15612419 165-186
HP 4169 ESNISRRTAWGSWLQASAPYAIAPV GI-15611318 115-139
HP 4171 PTNFVLGANIAGFRKVASAMIAQG GI-15612066 424-447
HP 4174 LEDLLYLINRPAYANAKVSLQADF GI-15612087 159-182
HP 4175 GAIITGNYALQAKLTGALFSEDK GI-15612537 201-223
HP 4179 ELVALYQSAKALSAYWLEIE GI-15611341 413-432
HP 4181 GLIYFFLNANTPSQHGF GI-15612512 118-134
HP 4189 IKEYQYSGAFKAVFPLKVNQM GI-15612027 73-93
HP 4192 TPGLLQFYRSALAYQLRDE GI-15612041 297-315
HP 4193 FGQYKKLVNRFEGVLTGKGLTYGGS GI-15612066 176-200
HP 4197 ASPYKNMLSLTLNAANGTISVSG GI-15612049 405-427
HP 4198 LENYRSLNALFTRSLKKERPFDK GI-15612340 46-68
HP 4199 ALKIEGRTKSSYYAAQTTRIYRLA GI-15611225 250-273
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